Median PFS in previous trials with older adults
| Trial | Patient population | Median PFS |
| MRFOCUS215 | ‘Non-fit’ older or frail mCRC patients receiving upfront dose reduction | Median PFS was 3.5, 5.8, 5.2 and 5.8 months in the 5-FU monotherapy, FOLFOX, capecitabine monotherapy and CAPOX groups, respectively; a reasonable estimate for all patients is 5 months |
| AVEX33 | Older mCRC patients, no candidate for oxaliplatin or irinotecan | Median PFS 9.1 months for capecitabine+bevacizumab, 5.1 months for capecitabine monotherapy. |
| NORDIC916 | ‘Non-fit’ older mCRC patients | Median PFS 5.1 months for full-dose S-1, 6.2 months for reduced-dose oxaliplatin+S-1. 25% received bevacizumab. |
| SALTO34 | mCRC patients with median age 73 years (not specifically older patients) | Median PFS 8.2 months for capecitabine monotherapy, 8.4 months for S-1 monotherapy. |
AVEX, AVastin in the Elderly with Xeloda; CAPOX, capecitabine plus oxaliplatin; FOLFOX, folinic acid, fluorouracil, and oxaliplatin; 5-FU, Fluorouracil; mCRC, metastatic colorectal cancer; PFS, progression-free survival.